C Y T O R I. Personalized Cell Therapy A TRUSTED LEADER IN CELL THERAPY NASDAQ: CYTX
|
|
- Ira Holmes
- 5 years ago
- Views:
Transcription
1 C Y T O R I Personalized Cell Therapy A TRUSTED LEADER IN CELL THERAPY NASDAQ: CYTX
2 Safe Harbor Statement This presentation contains certain forward-looking statements about Cytori Therapeutics, Inc. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this presentation involve known and unknown risks that relate to Cytori s future events or future financial performance and the actual results could differ materially from those discussed in this presentation. Risks and uncertainties that may cause Cytori's actual results to differ materially from those discussed in the presentation can be found in the "Risk Factors" section of Cytori s Form 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. We would advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the United States Securities and Exchange Commission for a more detailed description of these risks. The forward-looking statements contained in this presentation represent Cytori s estimates and assumptions only as of the date of this presentation and Cytori undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this presentation as a result of new information, future events or changes in Cytori s expectations.
3 i. Business & Technology Overview ii. ATHENA Trial iii. BARDA iv. Commercial Growth v. Corporate C Y T O R I C E L L
4 The Future of Medicine: Cell Therapy
5 Unique Device Model: Point-of-Care Your tissue is processed right at the side of your bed CE Mark Approved in EU for tissue ischemia & wounds
6 Recurring Revenue Model A proprietary single-use consumable set is required for each procedure (Concept: Razor-blade)
7 Platform: Many Indications VASCULAR Heart failure Heart attack PVD / PAD Liver Cirrhosis Kidney Injury Stroke Other TISSUE Fistula Wounds Incontinence Sports / Ortho Tissue Ischemia Breast Recon/Aug Radiation / Burn
8 Clinical Leadership Today Thousands of patients around the world have been treated using their own cells with Cytori products
9 Annuity Business Model Worldwide Opportunity (Est. 25,000 Hospitals) % Hospitals Penetrated Number of Hospitals Proc. Per Week Cartridge ASP ** Annual Revenue 10% 2,500 3 $5,000 $2 billion 20% 5,000 3 $5,000 $4 billion 30% 7,500 3 $5,000 $6 billion A few uses per week drives Significant revenue **Cartridge ASP expected to be at least $5,000; Est. $2,500 in tissue, $8-12,000 in vascular
10 Strategy i. Establish ADRC s as the standard for cells in the emerging Regenerative Medicine field (Device / Tool claims) ii. Develop market access for specific targeted indications (Therapeutic Claims)
11
12
13 Application Software Operating System
14 Application Software Operating System TRANSLATIONAL MEDICINE
15 Device / Tool Claims
16 Device / Tool Claims
17 Device / Tool Claims
18 Device / Tool Claims INTRAVASE Device Tissue No Option CMI Broad Vascular Access - AMI - PVD / PAD - CHF - Liver - Stroke - Kidney
19 Therapeutic Products Tissue
20 i. Business and Technology Overview ii. ATHENA Trial iii. BARDA iv. Commercial Growth v. Corporate C Y T O R I C E L L
21 Refractory Heart Failure Condition: Severe form of coronary artery disease due to chronic myocardial ischemia and leads to death Disease Course: Declining cardiac function leads to heart transplantation or death Size of Market: Approx.120K to 250K diagnosed each year in U.S. (subset of approx. 5.8 MM heart failure patients) Cytori Cell Therapy: Potential to revive living but stressed heart tissue; Halt progressive disease & keep patient off transplant list; overcome limits of existing drugs, devices and surgical options
22 ADRCs may preserve functional capacity, improve perfusion, reduce scar, improve left ventricular contractility and lead to lower mortality Safety: No malignant arrhythmias, adverse events similar in both groups; Harvesting ADRCs and transendocardial delivery is safe and feasible in patients with CAD MVO 2 & METS: Preserved function in ADRC at 6 & 18 months compared to controls (p=0.03, p=0.01) Total Left Ventricular Mass (MRI): ADRCs demonstrated significant improvement over controls (p<0.001) Wall Motion Score Index: ADRCs demonstrated significant improvement in wall motion score index (p<0.04) with a stabilization of scar size compared to controls Inducible Ischemia (SPECT): was reduced in ADRCs patients up to 18 months (p<0.05) Patient Age: Patient s in ADRCs group are 10 years older than placebo (65.8 vs 55.7 years; p=0.002) Cardiac Mortality: At 27 month follow-up, fewer ADRC patient deaths compared to controls PRECISE TRIAL (1 of 21 in ADRCs vs 2 of 6 Controls; p=0.10)
23 U.S. Refractory Heart Failure Trial Adipose-derived regenerative cells in the Treatment of patients with chronic ischemic HEart disease Not Amenable to surgical or interventional revascularization Objective Design Sample Size Study Location Dose: Endpoints To assess the safety and feasibility of Adipose-Derived Regenerative Cells delivered via an intramyocardial route in the treatment of chronic ischemic heart disease in patients who are not eligible for percutaneous or surgical revascularization Device-based (PMA/IDE) prospective, randomized, placebocontrolled, double-blind safety and feasibility clinical trial 45 Subjects, randomized 2:1 (ADRCs:Placebo) 6 centers in the United States 0.4 million cells/kg body weight - Clinical safety through 12 months - Peak oxygen consumption (VO 2 Max) at 6 months - Perfusion defect at 6 months - LV end-systolic and diastolic volume at 6 months - Ejection fraction at 6 months - Re-hospitalization, heart failure symptoms & quality of 12 mo
24 Refractory Heart Failure Status: All centers actively screening Minneapolis Heart Institute (Timothy Henry MD) Texas Heart Institute (Emerson Perin MD, PhD, James, Willerson, MD) University of Florida (Carl Pepine MD) University of South Florida (Leslie W. Miller MD) Scripps Green Hospital (Richard Schatz MD) Cardiology P.C. (Farrell Mendlesohn MD) Complete enrollment mid-summer month data first half 2014 Define Pivotal Trial Design Detailed protocol and trial size to be determined by ATHENA outcomes Likely endpoints to include a functional and composite clinical outcome
25 i. Business and Technology Overview ii. ATHENA Trial iii. BARDA iv. Commercial Growth v. Corporate C Y T O R I C E L L
26 Proof-of-Concept Success unlocks Options 1 & 2 up to $ 55 Million BARDA: Proof-of-Concept 1. ADRCs can be extracted from patients with thermal burn injury Availability 2. CT-X2 is as good as Celution 800 Processing 3. ADRCs from an irradiated animal improve healing of concomitant thermal burn Function $4.7 MM in funding Preclinical model Next-Gen Celution development Up to 2 years Proof-of-Con cept Options 1 & 2 Up to $55 MM Development including clinical Govt. has procurement ability Up to $45 MM Pivotal trial FDA submission Option 3
27 Smaller. Faster. Cheaper. Higher Yields. Product Evolution 1. Cytori developed interim Celution 800 System (Cytori) 2. Olympus designed Celution One System (OC-JV) 3. Cytori designed Next Gen System (BARDA)
28 i. Business and Technology Overview ii. ATHENA Trial iii. BARDA iv. Commercial Growth v. Corporate C Y T O R I C E L L
29 Commercial Growth to Profitability Japan Europe North America Emerging Markets Profitable region vascular & translational med 3 people Low-cost distributor model 2 people Minimal 2012 loss, Profitable in person Class 1 device designation 2H 2012 Tissue Ischemia CE Mark Intravascular CE Mark Puregraft approved in US & Canada CE Mark in Canada Pending Targeting select countries that recognize CE Mark Distributors and translation med to drive sales Intravascular IRB & translational medicine to drive sales PG extension + growing fat transfer to drive growth & build relationships Intravascular IRB sales Australia TGA approval pending % Rev 12: 52% 24% 13% 11% profitable investing near B/E near B/E 13: Profitable investing break-even profitable
30 Translational Medicine: Near-Term Revenue Driver Investigator-initiated trials resulting in: Meaningful sales to offset burn Expansion of physician and hospital network Radiation injury Vascular CE Mark Strategic benefit of development of new applications/pipeline Incontinence Pivotal trials, grants (BARDA), partnerships, regulatory approvals, reimbursement
31 Accelerating Revenue Growth 2013 Revenue Guidance of $15 Million $12 million in product sales $ 3 million in contract revenue (BARDA) Accelerate year over year revenue growth Positive contribution margin for full year Revenue Total product revenue of $8.7 million BARDA contract revenue of $0.4 million Total cash revenue of $9.1 million, 14% growth over 2011 Q4 gross profit of $2.6 million exceeded S&M expenses of $2.1 million
32 i. Business and Technology Overview ii. ATHENA Trial iii. BARDA iv. Commercial Growth v. Corporate C Y T O R I C E L L
33 Financials Current Select Data PF cash & AR (YE 2012) $32 MM Senior Term Loan (GE) $22 MM maturing in 2015 Shares outstanding Warrants 67 MM 10 $3.25 avg. exercise price 2013 Guidance Revenue SG&A R&D $15 MM ($12 m product, $3 m contract) Flat for year Slight increase, more than offset by BARDA revenue
34 57 Issued Patents; 75+ Pending DEVICES CURRENT DEVICES NEXT GENERATION COSMETIC & RECONSTRUCTIVE SURGERY CARDIOVASCULAR THERAPIES PIPELINE THERAPIES US: (6) CELUTION DEVICE ( 484) CELUTION DEVICE PLUS ADDITIVES ( 420) STEMSOURCE DEVICE ( 115) CELUTION DEVICE PLUS SENSORS FOR CLINICALLY SAFE OUTPUT ( 670) BEDSIDE COMPREHENSIVE DEVICE ( 059) CELUTION DEVICE CD31 POSITIVE CELLS ( 276) JAPAN: (2) CELUTION DEVICE ( 952) CELUTION FOR CLINICALLY SAFE OUTPUT ( 556) KOREA: (3) CELUTION DEVICE ( 995) STEMSOURCE DEVICE ( 812) CELUTION DEVICE ( 139) INDIA: (1) CELUTION DEVICE ( 706) AUSTRALIA: (2) CELUTION DEVICE ( 135) STEMSOURCE DEVICE ( 901) CHINA: (1) CELUTION DEVICE ( 689) US: (1) CELUTION & FUTURE GENERATIONS ( 075) CHINA: (1) CELUTION & FUTURE GENERATIONS ( 241) INDIA: (1) CELUTION WITH CENTRIFUGE OR FILTER ( 529) AUSTRALIA: (1) CELUTION WITH CENTRIFUGE OR FILTER ( 937) SINGAPORE: (1) CELUTION & FUTURE GENERATIONS ( 683) ISRAEL: (1) CELUTION WITH CENTRIFUGE OR FILTER ( 800) MEXICO: (1) CELUTION & FUTURE GENERATIONS ( 348) KOREA: (1) CELUTION WITH CENTRIFUGE OR FILTER ( 305) US: (6) CELUTION FOR MIXING ADRCS PLUS FAT ( 488) CELUTION OR NEXT GEN DEVICES FOR SOFT TISSUE DEFECTS ( 684) ADRCS PLUS FAT PLUS ADDITIVES ( 795) ADRCS PLUS FAT ( 672) ADRCS PLUS FAT COMPOSITION ( 121) CURRENT CELUTION DEVICE + FAT ( 947) JAPAN: (1) CELUTION AND NEXT GEN DEVICES FOR MIXING ADRCS PLUS FAT ( 041) KOREA: (3) ADRCS PLUS FAT ( 454) CELUTION OR NEXT GEN DEVICES FOR SOFT TISSUE DEFECTS ( 508) ADRCS PLUS FAT METHOD ( 666) EUROPE: (2) ADRCS FOR CARDIAC ( 382) OPPOSED DEVICE FOR RESTORING BLOOD FLOW ( 575) OPPOSED AUSTRALIA: (1) ADRCS FOR CARDIAC ( 858) SINGAPORE: (1) ADRCS FOR RESTORING BLOOD FLOW( 309) CHINA: (1) ADRCS FOR RESTORING BLOOD FLOW ( 104) HONG KONG: (1) ADRCS FOR RESTORING BLOOD FLOW ( 085) RUSSIA: (1) CELUTION FOR RESTORING BLOOD FLOW ( 924) SOUTH AFRICA: (1) ADRCS FOR CARDIAC ( 446) MEXICO: (1) CELUTION FOR RESTORING BLOOD FLOW ( 775) ISRAEL: (1) ADRCS FOR CARDIAC ( 354) CANADA: (1) ADRCS FOR RESTORING BLOOD FLOW( 510) US: (3) CELUTION FOR BONE ( 043) CELUTION OUTPUT PLUS PROSTHETIC FOR BONE RELATED DISORDERS ( 716) ADRCS FOR WOUND HEALING ( 580) EUROPE: (2) CELUTION FOR ACUTE TUBULAR NECROSIS ( 834) ADRCS FOR WOUND HEALING ( 833) JAPAN: (3) ADRCS FOR WOUND HEALING ( 699) CELUTION OUTPUT PLUS PROSTHETIC FOR BONE RELATED DISORDERS ( 119) CELUTION FOR PERIPHERAL VASCULAR DISEASE ( 511) INDIA: (1) ADRCS FOR WOUND HEALING ( 580) JAPAN: (1) CELUTION FOR RESTORING BLOOD FLOW( 787)
35 2013 Milestones Present / Publish PRECISE long-term data (18 months) - Advance BARDA toward Phase II - Partnership with Cash upfront - Complete patient enrollment in ATHENA by mid-summer Achieve 25 pts enrolled in ADVANCE; Add Canada - Achieve $15 million revenue target for 2013 (incl $2.5-3m Barda) - Expand PG line (PG-50) with 510k clearance & market launch - Define approval path with FDA for Refractory Heart Failure in US - Expand Celution approvals ( ie Canada, Australia) -
36 Personalized Cell C Y Therapy T O R I A T R U S T E D L E A D E R I N C E L L
Cell Therapy. Cytori Corporate Presentation January 2012
Cytori Corporate Presentation January 2012 Safe Harbor This presentation may contain certain forward-looking statements. All statements, other than statements of historical fact, that address activities,
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationForward-looking Statement Disclaimer
Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More information(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health. December 2018
(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health December 2018 Safe Harbor Statement All statements in this presentation that are not based on historical fact are forward looking statements.
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationForward Looking Statements and Further Information
JANUARY 2015 [ 1 ] Forward Looking Statements and Further Information SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationRevolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014
Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014 Forward-Looking Statements Statements contained herein that are not based on historical or current
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationNeovasc Inc. Alexei Marko, CEO. January 2012 OneMedForum
Neovasc Inc. Alexei Marko, CEO January 2012 OneMedForum 2 Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationPROFOUND MEDICAL CORP.
PROFOUND MEDICAL CORP. Pioneering a new standard of care in the treatment of prostate cancer Forward-Looking Statements This presentation and oral statements made during this meeting regarding Profound
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationSirtex Medical Limited (ASX:SRX)
Sirtex Medical Limited (ASX:SRX) Macquarie Australia Conference Mr Gilman Wong, CEO Dr David Cade, CMO Sydney, 8 th May 2014 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd 1 Understanding
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationNASDAQ: ELGX December Innovation that Empowers
NASDAQ: ELGX www.endologix.com December 2014 Innovation that Empowers Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationINTERIM RESULTS AS OF MARCH 31, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF MARCH 31, 2014 Q1 MAY 14, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 1.7 million doses delivered to the SNS during Q1 Full year financial expectations maintained DKK million
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationNeovasc Inc. TSXV: NVC
Neovasc Inc. TSXV: NVC Alexei Marko, CEO Chris Clark, CFO April 2013 Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation
More informationMedifocus, Inc. OTCQX: MDFZF TSXV: MFS
Medifocus, Inc. OTCQX: MDFZF TSXV: MFS www.medifocusinc.com Develops and commercializes minimally invasive focused heat thermotherapy systems for the treatment of cancer and other diseases January 2014
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationEnhancing lives through novel cell therapies. Cytori Therapeutics. Corporate Update I September 2016 NASDAQ: CYTX
Enhancing lives through novel cell therapies Cytori Therapeutics Corporate Update I September 21 NASDAQ: CYTX Forward Looking Statements and Disclaimers This presentation contains certain forward-looking
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationLivaNova Investor Day
LivaNova Investor Day TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) Paul Buckman General Manager, TMVR September 14, 2017 Safe Harbor Statement Certain statements in this presentation, other than purely
More informationA world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP
A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationNot an Offer for Securities
Not an Offer for Securities This presentation has been prepared by REVA Medical, Inc. (REVA or the Company) solely for its use at presentations to be made by the Company. This presentation does not constitute
More informationChronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America
Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America Chronic Care represents more than 75% of Coloplast sales and we
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationRecovering Hearts. Saving Lives.
Recovering Hearts. Saving Lives ṬM The Door to Unload (DTU) STEMI Safety & Feasibility Pilot Trial November 218 Recovering Hearts. Saving Lives. LEGAL DISCLAIMERS This presentation includes select slides
More informationInvestor Presentation
Investor Presentation January 2012 Forward Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933,
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationconfidently live life with ease Management Presentation
confidently live life with ease Management Presentation 1 Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause
More informationFor personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT
ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationFY06 Full Year Update & Overview
FY06 Full Year Update & Overview Investment Highlights Leading player in heated humidification systems Consistent growth strategy Estimated US$2+ billion and growing market opportunity High level of innovation
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More informationMAKO Surgical Corp. January MAKO Surgical Corp
MAKO Surgical Corp. January 2012 MAKO Surgical Corp. 2012 1 Forward Looking Statement This presentation contains forward-looking statements regarding, among other things, statements related to expectations,
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More information- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationCOMPANY OVERVIEW. July 30, 2018
COMPANY OVERVIEW July 30, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationAnnual Results 2017 & Business Update 13 April 2018
Annual Results 2017 & Business Update 13 April 2018 1 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements and information. Forward-looking statements are subject
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
More information